SYDNEY, June 4, 2026 /PRNewswire/ -- Shoplazza, a global AI-native eCommerce platform, is helping Australian merchants move faster from product idea to online store...
Lazada Seller & Partner Awards 2025 demonstrates Lazada's strengthened commitment to accelerating Indonesia's digital economy ahead of its year-end shopping festival series in 2025.
JAKARTA,...
MediPharm Labs holds unique US Food and Drug Administration (FDA) site registration in relation to the manufacturing and release of pharmaceutical cannabis products. MediPharm...
Centric PLM centralizes private label product development in a single, actionable source of truth
CAMPBELL, Calif., July 29, 2025 /PRNewswire/ -- Centric Software® is pleased...
DELRAY BEACH, Fla., July 14, 2025 /PRNewswire/ -- According to MarketsandMarkets™, the global Product Engineering Services Market size is projected to reach 1,800.45 billion...
DELRAY BEACH, Fla., July 14, 2025 /PRNewswire/ -- According to MarketsandMarkets™, the global Product Engineering Services Market size is projected to reach 1,800.45 billion...
TORONTO, June 16, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, wishes to respond to a misleading press release published earlier today by Apollo Technology Capital Corporation (“Apollo”) prematurely claiming that it considers the results of the annual and special meeting of shareholders scheduled to take place at 3:00 p.m. today (the “Meeting”) to be a clear victory for Apollo.